Innocan Pharma Corporation has granted its first patent in India for its Liposomal CBD Injection platform. This patent protects the company’s synthetic Cannabidiol-loaded Liposome Injection Platform (LPT-CBD), designed for precise dosing and sustained release of synthetic CBD into the bloodstream.
The LPT-CBD platform has received positive feedback from the U.S. Food and Drug Administration (FDA) following a successful pre-Investigational New Drug (pre-IND) meeting, advancing its development as a non-opioid alternative for chronic pain management.
Developed in collaboration with Professor Chezy Barenholz and Dr. Ahuva Cern from the Hebrew University in Jerusalem, the liposomal drug delivery platform allows for prolonged exposure and maximizes the bioavailability and therapeutic effects of cannabinoids.
This granted patent enhances Innocan’s proprietary value in India’s $55 billion pharmaceutical market, complementing its global patent applications and strengthening its position in the cannabinoid-based therapeutic sector.
Innocan Pharma’s CEO, Iris Bincovich, expressed his views about the patent grant and highlighted the company’s commitment to innovation and the advancement of non-opioid alternatives for chronic pain management.
This development in IP underscores Innocan Pharma’s dedication to expanding its intellectual property portfolio and advancing cannabinoid-based therapies on a global scale.
